Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Sarepta Therapeutics (SRPT) Data 'Positive but Some Questions Remain' - Mizuho
May 3, 2021 1:43 PM EDTMizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.
Yang commented, "The data was in line with our "base case"... More
Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) on Positive 5051 Update
May 3, 2021 11:58 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $166.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company reported updated clinical results from its multi-dose ascending study of SRP-5051, its exon 51 skipping PPMO in Duchenne Muscular Dystrophy (DMD).
Messer commented,... More
Sarepta Therapeutics (SRPT) Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021 8:50 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051, its next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
In biopsies taken at a median of 12 weeks and after only three doses, results from Part A of MOMENTUM study found that the 30 mg/kg of SRP-5051 dosed monthly... More
